Press release from Companies
Published: 2014-06-11 13:55:54
WntResearch AB today announces that Professor Andersson’s research group at Lund University has got a paper accepted for publication in Molecular Oncology (see publication list on the home page). In this paper the authors show that one important factor (IL-6) that promotes invasion and tumour metastasis in patients melanoma mediates its action through Wnt-5a. This ability of IL-6 effectively blocked by the peptide Box-5. These findings will potentially broaden the therapeutic use of Box-5 in the treatment of melanoma patients.
CEO Nils Brünner comments: “I’m happy that the science behind Box-5 is building up and strengthening WntResearch’s pipeline. Box-5 is currently in the pre-clinical phase following the lead candidate Foxy-5 that is in a clinical Phase 1 study in cancer patients with solid tumors except malignant melanoma.” For further information please contact: Nils Brünner, CEO E-mail: firstname.lastname@example.org Telephone: +45 2614 4708 About Foxy-5 Foxy-5 is an anti-metastatic drug candidate in clinical Phase 1. Foxy-5 represents a new concept (first-in-class) in the treatment of cancer. The drug candidate aims directly at the metastatic process. The spread of the tumor is the most common reason of death for cancer patients. Foxy-5 is one of the first anti-metastatic drug candidates to be investigated in the clinical setting. Foxy-5 offers a potential shift in the anticancer treatment paradigm in the treatment of many large cancer indications including breast-, colon, and prostate cancer. About WntResearch WntResearch (WNT.ST) is a public company listed at AktieTorget. WntResearch is developing novel anti-metastatic therapies for the treatment of cancer patients with metastasis. The company’s lead product Foxy-5 is in phase 1 and Box-5 is in pre-clinical phase. The company is focusing on Foxy-5.